Insulet Corporation (ETR:GOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 8.27B -55.9% |
| Revenue (ttm) | 2.67B +29.4% |
| Net Income | 328.50M +59.0% |
| EPS | 4.64 +59.4% |
| Shares Out | n/a |
| PE Ratio | 25.35 |
| Forward PE | 19.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 120.25 |
| Previous Close | 120.55 |
| Day's Range | 119.70 - 120.25 |
| 52-Week Range | 113.35 - 151.05 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controll... [Read more]
Financial Performance
In 2025, Insulet's revenue was $2.71 billion, an increase of 30.73% compared to the previous year's $2.07 billion. Earnings were $247.10 million, a decrease of -40.93%.
Financial numbers in USD Financial StatementsNews
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
Insulet Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Strong growth continues with robust international expansion and high post-90-day retention rates. Four corrective actions target early type 2 attrition, while Omnipod Discover and Omnipod 6 drive innovation. Operational readiness and quality improvements support sustained leadership.
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Insulet Transcript: Wells Fargo 21st Annual Healthcare Conference
Guidance was lowered due to higher attrition in type 2 diabetes, but corrective actions and a robust innovation pipeline are expected to drive future growth. U.S. and international growth rates will moderate, with stable pricing and continued investment in operational scale and new product launches.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 31, 2026 in Insulet Corporation Lawsuit - PODD
Notice to Pension Funds, Asset Managers, and Fiduciaries Holding PODD: Institutional Portfolios Face Significant Exposure Following Two Omnipod Medical Device Corrections and Over $90 Per Share Declin...
Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will prese...
Contact Robbins LLP for Information About Leading the Lawsuit That Alleges Insulet Corporation Misled Investors Regarding the Safety and Reliability of its Insulin Delivery Products
SAN DIEGO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Insu...
Insulet Corporation Investors With Significant Losses Must Act By August 31, 2026
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investors of the August 31, 2026 deadline to seek the role of le...
This Medtech Beat Earnings Estimates. It's the Worst S&P 500 Stock Today.
Insulet lowers its full-year revenue growth outlook, even after earnings and revenue handily beat expectations.
Insulet Slides: Investor presentation
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Insulet cuts sales growth forecast on slower US insulin-pump sales; shares fall
Insulet lowered its annual sales growth forecast on Wednesday, pointing to a softer second half of 2026 particularly for U.S. sales of its Omnipod insulin pumps, sending shares of the company down m...
Insulet Earnings Call Transcript: Q2 2026
Q2 saw 23% revenue growth, margin expansion, and strong EPS, driven by robust demand and international momentum. Lower retention among Type 2 customers led to revised guidance, with new initiatives underway to improve onboarding and support. Long-term growth prospects remain strong.
Insulet Earnings release: Q2 2026
Insulet released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Insulet Slides: Q2 2026
Insulet has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Insulet Quarterly report: Q2 2026
Insulet has published its Q2 2026 quarterly earnings report on August 5, 2026.
Insulet Reports Second Quarter 2026 Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
PODD INVESTOR REMINDER: Insulet Corporation Investors Have Until August 31, 2026 To Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)---- $PODD #classaction--If you have suffered a loss on your Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) investment, contact Lauren Molinaro of Kirby McIne...
$PODD Fraud Notification: Insulet Sued for Fraud Over Misrepresentations about its Safety Issues – Investors Notified to Contact BFA Law
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ:PODD) and c...
Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a...
PODD Investors Have Rights - If You Lost Money Investing in Insulet Corporation Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, July 13, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD...
INSULET CORPORATION (PODD) INVESTOR ALERT Investors With Large Losses in Insulet Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Insulet Slides: Investor presentation
Insulet has posted slides in relation to its latest quarterly earnings report, which was published on July 6, 2026.
Grabar Law Office Investigates Claims on Behalf of Shareholders of Insulet Corporation (PODD)
Philadelphia, Pennsylvania--(Newsfile Corp. - July 3, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ: PODD). WHAT IS THIS INVESTIGATION ABOU...
Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
